세계의 입 주위 피부염 치료 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2030년)

The global demand for Perioral Dermatitis Treatment Market is presumed to reach the market size of nearly USD 121.15 MN by 2030 from USD 69 MN in 2022 with a CAGR of 7.29% under the study period 2023 - 2030.

Perioral dermatitis is a skin condition which is characterized by the presence of small, red bumps or papules around the mouth, nose, and sometimes the eyes. It can cause itching, burning, and mild discomfort. The treatment of perioral dermatitis typically involves a combination of self-care measures and medical interventions.

MARKET DYNAMICS:

The increasing prevalence of perioral dermatitis and greater awareness of the condition drive the demand for effective treatments. Its impact on quality of life, causing discomfort and self-consciousness, motivates individuals to seek treatment options. Advancements in medical research play a crucial role in driving the market as ongoing studies focus on understanding the condition and developing new treatment approaches. Recommendations from dermatologists and healthcare professionals influence the market as they diagnose the condition, prescribe treatments, and provide ongoing care. Patient preferences and experiences also shape the market, as positive outcomes and word-of-mouth recommendations influence the choices of individuals seeking treatment. The efficacy and safety of treatment options are key drivers, with individuals seeking treatments that have demonstrated effectiveness in reducing symptoms and improving skin appearance while minimizing side effects. Regulatory frameworks and guidelines for dermatological treatments impact the market, affecting the availability and accessibility of specific treatment options.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of perioral dermatitis treatment. The growth and trends of perioral dermatitis treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the perioral dermatitis treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Diagnosis

• Skin Biopsy
• Physical Examination
• Others

By Treatment

• Antibiotics
• Topical Ivermectin
• Immunosuppressive Agents
• Others

By End-User

• Homecare
• Specialty Clinics
• Hospitals
• Others

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Perioral Dermatitis Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Perioral Dermatitis Treatment market include Pfizer Inc., Novartis International AG, Johnson & Johnson, Roche Holding AG, Merck & Co., Inc., GlaxoSmithKline plc, AstraZeneca plc, Sanofi SA, AbbVie Inc., Gilead Sciences, Inc., Bristol Myers Squibb Company, Eli Lilly and Company, Novo Nordisk A/S, Amgen Inc., Teva Pharmaceutical Industries Ltd., Bayer AG, Takeda Pharmaceutical Company Limited, Moderna, Inc., Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc., Biogen Inc., Celgene Corporation, Astellas Pharma Inc., and Alexion Pharmaceuticals, Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . PERIORAL DERMATITIS TREATMENT - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Diagnosis
  • 3.7.2 Market Attractiveness Analysis By Treatment
  • 3.7.3 Market Attractiveness Analysis By End-User
  • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL PERIORAL DERMATITIS TREATMENT MARKET ANALYSIS BY DIAGNOSIS

• 5.1 Overview by Diagnosis
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Diagnosis
• 5.4 Skin Biopsy Historic and Forecast Sales by Regions
• 5.5 Physical Examination Historic and Forecast Sales by Regions
• 5.6 Others Historic and Forecast Sales by Regions

6 . GLOBAL PERIORAL DERMATITIS TREATMENT MARKET ANALYSIS BY TREATMENT

• 6.1 Overview by Treatment
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Treatment
• 6.4 Antibiotics Historic and Forecast Sales by Regions
• 6.5 Topical Ivermectin Historic and Forecast Sales by Regions
• 6.6 Immunosuppressive Agents Historic and Forecast Sales by Regions
• 6.7 Others Historic and Forecast Sales by Regions

7 . GLOBAL PERIORAL DERMATITIS TREATMENT MARKET ANALYSIS BY END-USER

• 7.1 Overview by End-User
• 7.2 Historical and Forecast Data
• 7.3 Analysis by End-User
• 7.4 Homecare Historic and Forecast Sales by Regions
• 7.5 Specialty Clinics Historic and Forecast Sales by Regions
• 7.6 Hospitals Historic and Forecast Sales by Regions
• 7.7 Others Historic and Forecast Sales by Regions

8 . GLOBAL PERIORAL DERMATITIS TREATMENT MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2. North America By Segment Sales Analysis
  • 8.3.3. North America By Country Sales Analysis
  • 8.3.4. United State Sales Analysis
  • 8.3.5. Canada Sales Analysis
  • 8.3.6. Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2. Europe by Segment Sales Analysis
  • 8.4.3. Europe by Country Sales Analysis
  • 8.4.4. United Kingdom Sales Analysis
  • 8.4.5. France Sales Analysis
  • 8.4.6. Germany Sales Analysis
  • 8.4.7. Italy Sales Analysis
  • 8.4.8. Russia Sales Analysis
  • 8.4.9. Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2. Asia Pacific by Segment Sales Analysis
  • 8.5.3. Asia Pacific by Country Sales Analysis
  • 8.5.4. China Sales Analysis
  • 8.5.5. India Sales Analysis
  • 8.5.6. Japan Sales Analysis
  • 8.5.7. South Korea Sales Analysis
  • 8.5.8. Australia Sales Analysis
  • 8.5.9. Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2. Latin America by Segment Sales Analysis
  • 8.6.3. Latin America by Country Sales Analysis
  • 8.6.4. Brazil Sales Analysis
  • 8.6.5. Argentina Sales Analysis
  • 8.6.6. Peru Sales Analysis
  • 8.6.7. Chile Sales Analysis
  • 8.6.8. Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2. Middle East & Africa by Segment Sales Analysis
  • 8.7.3. Middle East & Africa by Country Sales Analysis
  • 8.7.4. Saudi Arabia Sales Analysis
  • 8.7.5. UAE Sales Analysis
  • 8.7.6. Israel Sales Analysis
  • 8.7.7. South Africa Sales Analysis
  • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE PERIORAL DERMATITIS TREATMENT COMPANIES

• 9.1. Perioral Dermatitis Treatment Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10 . COMPANY PROFILES OF PERIORAL DERMATITIS TREATMENT INDUSTRY

• 10.1. Company Share Analysis
• 10.2. Market Concentration Rate
• 10.3. Pfizer Inc.
  • 10.3.1. Company Overview
  • 10.3.2. Company Revenue
  • 10.3.3. Products
  • 10.3.4. Recent Developments
• 10.4. Novartis International AG
  • 10.4.1. Company Overview
  • 10.4.2. Company Revenue
  • 10.4.3. Products
  • 10.4.4. Recent Developments
• 10.5. Johnson & Johnson
  • 10.5.1. Company Overview
  • 10.5.2. Company Revenue
  • 10.5.3. Products
  • 10.5.4. Recent Developments
• 10.6. Roche Holding AG
  • 10.6.1. Company Overview
  • 10.6.2. Company Revenue
  • 10.6.3. Products
  • 10.6.4. Recent Developments
• 10.7. Merck & Co. Inc.
  • 10.7.1. Company Overview
  • 10.7.2. Company Revenue
  • 10.7.3. Products
  • 10.7.4. Recent Developments
• 10.8. GlaxoSmithKline plc
  • 10.8.1. Company Overview
  • 10.8.2. Company Revenue
  • 10.8.3. Products
  • 10.8.4. Recent Developments
• 10.9. AstraZeneca plc
  • 10.9.1. Company Overview
  • 10.9.2. Company Revenue
  • 10.9.3. Products
  • 10.9.4. Recent Developments
• 10.10. Sanofi SA
  • 10.10.1. Company Overview
  • 10.10.2. Company Revenue
  • 10.10.3. Products
  • 10.10.4. Recent Developments
• 10.11. AbbVie Inc.
  • 10.11.1. Company Overview
  • 10.11.2. Company Revenue
  • 10.11.3. Products
  • 10.11.4. Recent Developments
• 10.12. Gilead Sciences Inc.
  • 10.12.1. Company Overview
  • 10.12.2. Company Revenue
  • 10.12.3. Products
  • 10.12.4. Recent Developments
• 10.13. Bristol Myers Squibb Company
  • 10.13.1. Company Overview
  • 10.13.2. Company Revenue
  • 10.13.3. Products
  • 10.13.4. Recent Developments
• 10.14. Eli Lilly and Company
  • 10.14.1. Company Overview
  • 10.14.2. Company Revenue
  • 10.14.3. Products
  • 10.14.4. Recent Developments
• 10.15. Novo Nordisk A/S
  • 10.15.1. Company Overview
  • 10.15.2. Company Revenue
  • 10.15.3. Products
  • 10.15.4. Recent Developments
• 10.16. Amgen Inc.
  • 10.16.1. Company Overview
  • 10.16.2. Company Revenue
  • 10.16.3. Products
  • 10.16.4. Recent Developments
• 10.17. Teva Pharmaceutical Industries Ltd.
  • 10.17.1. Company Overview
  • 10.17.2. Company Revenue
  • 10.17.3. Products
  • 10.17.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies